accountAs Pfizer (PFE) faces the expiration of its patent on Lipitor and no likely blockbuster announcements in the near-future, the stock could be stuck in a holding pattern, writes Barclays analyst C. Anthony Butler in downgrading the stock to Equal Weight from Overweight. “Through year’s end, we foresee limited potential for upside surprises from R&D [...]
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Pfizer: Trouble Ahead in Post-Lipitor World, Says Analyst - Stocks To Watch Today
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account